Skip to main content
. 2018 Jun 7;8(13):3544–3558. doi: 10.7150/thno.24607

Figure 7.

Figure 7

In vivo antitumor efficacy of ZHPV16 E7 affitoxin384. Therapeutic efficacy of ZHPV16 E7 affitoxin384 was studied using SiHa tumor-bearing mice by two methods. (A) SiHa tumor-bearing mice were prepared in advance, followed by injection of ZHPV16 E7 affitoxin384, Zwt affitoxin, ZHPV16 E7 384, PE38KDEL, or PBS every three days for 6 times via tail vein. The therapeutic efficacies of affitoxin proteins were evaluated based on daily measurements of tumor volume and body weight. (B) Tumors from mice in (A) were separated. (C) All tumors from (B) were weighed and compared. (D) When SiHa tumor-bearing mice were prepared, cells and ZHPV16 E7 affitoxin384, Zwt affitoxin, ZHPV16 E7 384, PE38KDEL, or PBS were injected at the same time. The therapeutic efficacies of affitoxin proteins were evaluated based on daily measurements of tumor volume and body weight. (E) Tumors from mice in (D) were isolated. (F) All tumors from (E) were weighed and compared. Data are given as mean ± SD (n=5). *P <0.05 versus the control group.